公开(公告)号：US20210093654A1

公开(公告)日：2021-04-01

申请号：US16634675

申请日：2018-07-30

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K31/713 ,  C12N15/113 ,  A61P35/00

Abstract: The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US20210137922A1

公开(公告)日：2021-05-13

申请号：US16476220

申请日：2018-01-08

Applicant: LEMONEX INC.

Inventor： Jae Ho LEE ,  Dal-Hee MIN ,  Cheolhee WON

IPC: A61K31/506 ,  A23L33/10 ,  A61K31/337 ,  A61K31/475 ,  A61K31/165 ,  A61K31/343 ,  A61K33/243 ,  A61P35/04

Abstract: A method for treatment of cancer selected from the group consisting of metastatic ovarian cancer, endometrial cancer, and breast cancer includes administering a composition comprising a compound represented by Formula 1, a pharmaceutically acceptable salt thereof to a subject in need thereof: The composition can efficiently kill cancer cells present in a spheroid form, thereby being usefully applied as novel medicament for metastatic ovarian cancer, endometrial cancer or breast cancer.

公开(公告)号：US20180306718A1

公开(公告)日：2018-10-25

申请号：US15765409

申请日：2016-06-15

Applicant: LEMONEX INC.

Inventor： Cheolhee WON ,  Dal-Hee MIN

IPC: G01N21/64 ,  C12N15/115 ,  C12N1/20 ,  C08B37/08 ,  G01N33/574

Abstract: A quencher containing water-soluble polymer-conjugated nanomaterial effectively quenches the fluorescence of a fluorescent material-conjugated probe. In addition, a composition including the quencher and a fluorescent material-conjugated probe can detect a target material existing at a low concentration, and thus can be favorably used as a composition or kit for providing information necessary for the detection of a biomaterial or the diagnosis of a disease.

公开(公告)号：US20250032414A1

公开(公告)日：2025-01-30

申请号：US18910379

申请日：2024-10-09

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

公开(公告)号：US20200009054A1

公开(公告)日：2020-01-09

申请号：US16483830

申请日：2018-02-06

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  A61K31/713 ,  A61K31/711 ,  A61K39/395 ,  A61K38/46

Abstract: A bioactive substance carrier includes a bioactive substance, and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US20220072027A1

公开(公告)日：2022-03-10

申请号：US17536880

申请日：2021-11-29

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K31/713 ,  A61P35/00 ,  C12N15/113

Abstract: The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US20200163885A1

公开(公告)日：2020-05-28

申请号：US16633849

申请日：2018-07-25

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61L24/02 ,  A61L24/00 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  C12N15/113 ,  A61K38/38 ,  C07K16/28 ,  A61K38/46 ,  A61K49/04

Abstract: A composition including porous silica particles according to an embodiment of the present invention may effectively deliver a bioactive material to target tissues or cells in the blood stream by modifying surfaces of the particles to inhibit aggregation and precipitation in the blood. An embolic composition including the composition may have an advantage of having specific physical properties such as biodegradability and sustained release thus to achieve excellent embolization effects and targetability toward target tumor tissues or cells, thereby reducing side effects.

公开(公告)号：US20240041771A1

公开(公告)日：2024-02-08

申请号：US18368097

申请日：2023-09-14

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

CPC classification number: A61K9/1611 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1758 ,  A61K38/465 ,  A61K39/395

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

公开(公告)号：US20210369614A1

公开(公告)日：2021-12-02

申请号：US17399320

申请日：2021-08-11

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

Abstract: A porous silica particles according to an embodiment of the present disclosure includes a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US20190071314A1

公开(公告)日：2019-03-07

申请号：US16122872

申请日：2018-09-05

Applicant: LEMONEX INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Dal-Hee MIN ,  Cheolhee WON ,  Sejin PARK ,  Seongchan KIM

IPC: C01B37/02 ,  C12N5/00 ,  A61K9/50 ,  A61K9/51 ,  B01J13/02 ,  B82Y5/00

Abstract: A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.